Daniel L. Morganstein
YOU?
Author Swipe
View article: Association between hyperglycaemia, diabetes complications and development of fibrotic conditions among people living with type 1 and type 2 diabetes in England: a retrospective cohort study using UK Clinical Resource Datalink Aurum and Hospital Episode Statistics
Association between hyperglycaemia, diabetes complications and development of fibrotic conditions among people living with type 1 and type 2 diabetes in England: a retrospective cohort study using UK Clinical Resource Datalink Aurum and Hospital Episode Statistics Open
Objective Fibrosis is a pathological feature that can occur in a wide range of diseases including diabetes mellitus. We investigated whether in people with type 1 (T1DM) or type 2 diabetes mellitus (T2DM), glycaemia or diabetes-related com…
View article: Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in England
Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in England Open
There was robust evidence that people with T2DM had higher cardiovascular and respiratory disease mortality following lung cancer diagnosis. The relationships between T2DM and all-cause and cancer-specific mortality were highly sensitive t…
View article: Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer
Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer Open
Medullary thyroid cancer (MTC) is a rare subtype of thyroid cancer originating from parafollicular C-cells of the thyroid. Tyrosine kinase inhibitors are used to treat patients with advanced MTC. Selpercatinib is a highly selective RET inh…
View article: Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer
Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer Open
Objective Type 2 diabetes mellitus (T2DM) and cancer are prevalent conditions, with evidence linking T2DM to higher breast cancer incidence and mortality. However, it is uncertain whether excess mortality in breast cancer patients with dia…
View article: Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Scatter diagram with regression line summarizing the linear regression analysis between the median baseline glycaemia (used as independent variable: x-axes) and median baseline NLR (used as dependent variable: y-axes). 133 patients include…
View article: Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not re…
View article: Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes…
View article: Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.
View article: Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival whole cohort; patients on more than one diabetes medications: 15.5 months (95%CI: 11.1-20.6; 79 events), patients on one medication: 12.5 …
View article: Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not re…
View article: Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Tumour micron-environment transcriptome analysis.
View article: Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
View article: Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
View article: Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on other oral antidiabetic drugs and insulin therapy: 17.5 months (95%CI: 12.8-20.9; 82 …
View article: Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Details of diabetes medications.
View article: Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts identified in diabetic samples (n = 11) versus non-diabetic controls (n = 11). …
View article: Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), patients not receiving metformin: 19.0 months (95%CI: 16.4 – 21.1; …
View article: Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes…
View article: Supplementary Table S11 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S11 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics of patients included in the targeted transcriptome analysis.
View article: Supplementary Table S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
NSCLC cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:1, caliper 0.1).
View article: Supplementary Table S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).
View article: Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.
View article: Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts identified in diabetic samples (n = 11) versus non-diabetic controls (n = 11). …
View article: Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.